122 related articles for article (PubMed ID: 37737557)
1. Identification of highly potent 2,4-diarylaminopyrimidine analogs of a typical piperidinyl-4-ol moiety as promising antitumor ALK inhibitors.
Liu S; Wang F; Yang J; Su G; Cao Z; Shan M; Zhai X
Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300416. PubMed ID: 37737557
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel ALK inhibitors.
Wang X; Hu Y; Zou X; Wang P; Yue H; Guo M; Li Z; Gong P
Bioorg Med Chem; 2022 Jul; 66():116794. PubMed ID: 35576654
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
4. Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects.
Li Z; Guo M; Cao M; Zhao T; Li M; Zhai X
Bioorg Med Chem; 2021 May; 37():116108. PubMed ID: 33756437
[TBL] [Abstract][Full Text] [Related]
5. Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.
Guo M; Zuo D; Zhao T; Li X; Cao J; Qiu Y; Wei S; Zhai X
Eur J Med Chem; 2021 Mar; 214():113259. PubMed ID: 33581554
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors.
Yang J; Ma D; Liu S; Tan Z; Guo M; Cao Z; Zhang J; Zhai X
Eur J Med Chem; 2022 Nov; 241():114626. PubMed ID: 35939995
[TBL] [Abstract][Full Text] [Related]
7. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives.
Guo M; Zuo D; Zhang J; Xing L; Gou W; Jiang F; Jiang N; Zhang D; Zhai X
Eur J Med Chem; 2018 Oct; 158():322-333. PubMed ID: 30223120
[TBL] [Abstract][Full Text] [Related]
8. Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants.
Guo M; Wang H; Yang J; Wang X; Zhang J; Liu S; Wei S; Jiang N; Zhai X
Eur J Med Chem; 2022 Aug; 238():114493. PubMed ID: 35691173
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects.
Li T; Li C; Yang J; Guo M; Cao Z; Wang X; Jiang N; Zhai X
Bioorg Med Chem; 2021 Oct; 47():116396. PubMed ID: 34534734
[TBL] [Abstract][Full Text] [Related]
10. Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.
Zhu M; Li W; Zhao T; Chen Y; Li T; Wei S; Guo M; Zhai X
Bioorg Med Chem; 2020 Oct; 28(20):115719. PubMed ID: 33069075
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects.
Cao Z; Zhang J; Guo M; Shao B; Wei X; Li S; Wang P; Zhai X
Bioorg Chem; 2023 Jul; 136(